SCHEMBL7315751

SCHEMBL7315751

Clc1cc(CCc2ccccn2)c2oc(-c3cnccn3)nc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.43
NPC1 O15118 6/20 0.43
HSD17B10 Q99714 5/20 0.43
TP53 P04637 4/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
KDM4E B2RXH2 4/20 0.43
ALDH1A1 P00352 4/20 0.43
HPGD P15428 3/20 0.43
PIEZO1 Q92508 5/20 0.41
CYP1A2 P05177 2/20 0.37
CYP2D6 P10635 1/20 0.37
TERT O14746 2/20 0.37
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
CCR1 P32246 1/20 0.35
CCR5 P51681 1/20 0.35
CCR8 P51685 1/20 0.35
PKM P14618 3/20 0.34
HRH4 Q9H3N8 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7324311 0.85 KDM4E (0.40) RAB9ANPC1HSD17B10TP53SMN1; SMN2
SCHEMBL7322971 0.84 NPC1 (0.41) RAB9ANPC1HSD17B10TP53SMN1; SMN2
SCHEMBL7317091 0.81 PDGFRB (0.38) RAB9ANPC1HSD17B10TP53SMN1; SMN2
SCHEMBL7315804 0.80 ALDH1A1 (0.36) RAB9ANPC1HSD17B10TP53SMN1; SMN2
SCHEMBL7321855 0.79 KDM4E (0.36) RAB9ANPC1HSD17B10TP53SMN1; SMN2
SCHEMBL7314123 0.79 KDM4E (0.37) RAB9ANPC1HSD17B10TP53SMN1; SMN2
SCHEMBL7317490 0.78 KDM4E (0.40) RAB9ANPC1HSD17B10TP53SMN1; SMN2
SCHEMBL7318937 0.78 CHRNA7 (0.38) RAB9ANPC1HSD17B10TP53SMN1; SMN2
SCHEMBL7324755 0.78 ALDH1A1 (0.37) RAB9ANPC1HSD17B10TP53SMN1; SMN2
SCHEMBL7322773 0.77 CYP2D6 (0.36) RAB9ANPC1HSD17B10TP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6166041-A 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma EURO-CELTIQUE, S.A. (LU) 2000-12-26 US disclosed